近期维生素K拮抗剂使用与急性缺血性卒中血管内血栓切除术后颅内出血
基于美国心脏协会Get With the Guidelines-Stroke项目2015年10月至2020年3月594家医院32715例在最后正常时间6小时内接受血管内血栓切除术的急性缺血性卒中患者,回顾性队列分析显示,入院前7天内使用VKA者占9.4%(中位INR 1.5),总体症状性颅内出血风险与未使用者无显著差异(6.8% vs 6.4%,调整OR 1.12,95%CI 0.94-1.35)。亚组分析中,VKA使用且入院INR>1.7者症状性颅内出血风险显著高于未使用抗凝剂者(8.3% vs 6.4%,调整OR 1.88,95%CI 1.33-2.65),而INR≤1.7者无显著差异。5项预设次要终点均无显著差异。提示对近期使用VKA且INR>1.7的患者行EVT需警惕症状性颅内出血风险。
要点
- 近期使用VKA且入院INR>1.7的患者,EVT后症状性颅内出血风险显著高于未使用抗凝剂者(8.3% vs 6.4%,调整OR 1.88,95%CI 1.33-2.65)。
- 近期使用VKA且INR≤1.7的患者,症状性颅内出血风险与未使用者无显著差异(6.7% vs 6.4%,调整OR 1.24,95%CI 0.87-1.76)。
- 总体VKA使用组与未使用组症状性颅内出血风险无显著差异(6.8% vs 6.4%,调整OR 1.12,95%CI 0.94-1.35)。
- 5项预设次要终点(危及生命的系统性出血、其他严重并发症、再灌注治疗并发症、院内死亡、院内死亡或出院转临终关怀)在VKA暴露组与未暴露组间均无显著差异。
- 研究纳入32715例在最后正常时间6小时内接受EVT的患者,其中9.4%有近期VKA使用史(中位INR 1.5,IQR 1.2-1.9)。
适用人群与场景
- 美国594家医院中,2015年10月至2020年3月因大血管闭塞所致急性缺血性卒中、在最后正常时间6小时内被选择接受血管内血栓切除术的成人患者(中位年龄72岁,50.7%女性)。
诊断标准与关键阈值
- 暴露定义为入院前7天内使用VKA。
- 入院时国际标准化比值(INR)>1.7为亚组分析阈值。
红旗征与不能漏的情况
- 近期使用VKA且入院INR>1.7的患者,EVT后症状性颅内出血风险显著增加(8.3% vs 6.4%,调整OR 1.88,95%CI 1.33-2.65)。
研究设计与关键结果
- 研究类型:回顾性观察性队列研究,基于美国心脏协会Get With the Guidelines-Stroke项目,纳入594家医院32715例患者。
- 暴露与对照:3087例(9.4%)入院前7天内使用VKA(中位INR 1.5,IQR 1.2-1.9),29628例未使用VKA。
- 主要终点:总体VKA使用与未使用组症状性颅内出血风险无显著差异(6.8% [211/3087] vs 6.4% [1904/29628];调整OR 1.12,95%CI 0.94-1.35;调整风险差0.69%,95%CI -0.39%至1.77%)。
- 亚组:VKA使用且INR>1.7者(n=830)症状性颅内出血风险显著高于未使用VKA者(8.3% vs 6.4%;调整OR 1.88,95%CI 1.33-2.65;调整风险差4.03%,95%CI 1.53%-6.53%)。
- 亚组:VKA使用且INR≤1.7者(n=1585)症状性颅内出血风险与未使用VKA者无显著差异(6.7% vs 6.4%;调整OR 1.24,95%CI 0.87-1.76;调整风险差1.13%,95%CI -0.79%至3.04%)。
- 次要终点:5项预设次要终点(危及生命的系统性出血、其他严重并发症、再灌注治疗并发症、院内死亡、院内死亡或出院转临终关怀)在VKA暴露组与未暴露组间均无显著差异。
证据类型、等级与局限
- 证据类型:回顾性观察性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于近期使用VKA且入院INR>1.7的急性缺血性卒中患者,行EVT前应充分评估症状性颅内出血风险。
- 对于近期使用VKA但INR≤1.7的患者,EVT后症状性颅内出血风险与未使用抗凝剂者无显著差异。
指南或共识出处
- 美国心脏协会Get With the Guidelines-Stroke项目,2015年10月至2020年3月。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Use of oral vitamin K antagonists (VKAs) may place patients undergoing endovascular thrombectomy (EVT) for acute ischemic stroke caused by large vessel occlusion at increased risk of complications.
OBJECTIVE: To determine the association between recent use of a VKA and outcomes among patients selected to undergo EVT in clinical practice.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective, observational cohort study based on the American Heart Association's Get With the Guidelines-Stroke Program between October 2015 and March 2020. From 594 participating hospitals in the US, 32 715 patients with acute ischemic stroke selected to undergo EVT within 6 hours of time last known to be well were included.
EXPOSURE: VKA use within the 7 days prior to hospital arrival.
MAIN OUTCOME AND MEASURES: The primary end point was symptomatic intracranial hemorrhage (sICH). Secondary end points included life-threatening systemic hemorrhage, another serious complication, any complications of reperfusion therapy, in-hospital mortality, and in-hospital mortality or discharge to hospice.
RESULTS: Of 32 715 patients (median age, 72 years; 50.7% female), 3087 (9.4%) had used a VKA (median international normalized ratio [INR], 1.5 [IQR, 1.2-1.9]) and 29 628 had not used a VKA prior to hospital presentation. Overall, prior VKA use was not significantly associated with an increased risk of sICH (211/3087 patients [6.8%] taking a VKA compared with 1904/29 628 patients [6.4%] not taking a VKA; adjusted odds ratio [OR], 1.12 [95% CI, 0.94-1.35]; adjusted risk difference, 0.69% [95% CI, -0.39% to 1.77%]). Among 830 patients taking a VKA with an INR greater than 1.7, sICH risk was significantly higher than in those not taking a VKA (8.3% vs 6.4%; adjusted OR, 1.88 [95% CI, 1.33-2.65]; adjusted risk difference, 4.03% [95% CI, 1.53%-6.53%]), while those with an INR of 1.7 or lower (n = 1585) had no significant difference in the risk of sICH (6.7% vs 6.4%; adjusted OR, 1.24 [95% CI, 0.87-1.76]; adjusted risk difference, 1.13% [95% CI, -0.79% to 3.04%]). Of 5 prespecified secondary end points, none showed a significant difference across VKA-exposed vs VKA-unexposed groups.
CONCLUSIONS AND RELEVANCE: Among patients with acute ischemic stroke selected to receive EVT, VKA use within the preceding 7 days was not associated with a significantly increased risk of sICH overall. However, recent VKA use with a presenting INR greater than 1.7 was associated with a significantly increased risk of sICH compared with no use of anticoagulants.
参考来源
- Mac Grory B, Holmes DN, Matsouaka RA, et al. Recent Vitamin K Antagonist Use and Intracranial Hemorrhage After Endovascular Thrombectomy for Acute Ischemic Stroke. JAMA. 2023. PMID: 37338878. doi:10.1001/jama.2023.8073
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。